IN2014KN00948A - - Google Patents
Info
- Publication number
- IN2014KN00948A IN2014KN00948A IN948KON2014A IN2014KN00948A IN 2014KN00948 A IN2014KN00948 A IN 2014KN00948A IN 948KON2014 A IN948KON2014 A IN 948KON2014A IN 2014KN00948 A IN2014KN00948 A IN 2014KN00948A
- Authority
- IN
- India
- Prior art keywords
- same
- tautomer
- diastereomer
- enantiomer
- solvate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161543082P | 2011-10-04 | 2011-10-04 | |
PCT/US2012/058566 WO2013052550A2 (fr) | 2011-10-04 | 2012-10-03 | Nouveaux modulateurs du système immunitaire à base d'imidazole quinoline |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014KN00948A true IN2014KN00948A (fr) | 2015-08-21 |
Family
ID=48044383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN948KON2014 IN2014KN00948A (fr) | 2011-10-04 | 2012-10-03 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9873694B2 (fr) |
EP (1) | EP2763677B1 (fr) |
JP (1) | JP2014528449A (fr) |
AU (1) | AU2012318694B2 (fr) |
CA (1) | CA2850932A1 (fr) |
IL (1) | IL231957A0 (fr) |
IN (1) | IN2014KN00948A (fr) |
WO (1) | WO2013052550A2 (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
EA038972B1 (ru) | 2016-07-30 | 2021-11-16 | Бристол-Маерс Сквибб Компани | Диметоксифенилзамещенные соединения индола в качестве ингибиторов tlr7, tlr8 или tlr9 |
US10660877B2 (en) | 2016-09-09 | 2020-05-26 | Bristol-Myers Squibb Company | Pyridyl substituted indole compounds |
EP3661926B1 (fr) | 2017-08-04 | 2022-02-23 | Bristol-Myers Squibb Company | Composés indole substitués utiles en tant qu'inhibiteurs de tlr7/8/9 |
JP7266576B2 (ja) | 2017-08-04 | 2023-04-28 | ブリストル-マイヤーズ スクイブ カンパニー | [1,2,4]トリアゾロ[4,3-a]ピリジニル置換のインドール化合物 |
CN111448190B (zh) | 2017-11-14 | 2023-09-26 | 百时美施贵宝公司 | 取代的吲哚化合物 |
ES2960411T3 (es) | 2017-12-18 | 2024-03-04 | Bristol Myers Squibb Co | Compuestos de 4-azaindol |
WO2019126113A1 (fr) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Composés d'indole substitués utiles en tant qu'inhibiteurs de tlr |
SG11202005704RA (en) | 2017-12-19 | 2020-07-29 | Bristol Myers Squibb Co | 6-azaindole compounds |
CN111511730B (zh) | 2017-12-19 | 2023-07-25 | 百时美施贵宝公司 | 可用作tlr抑制剂的被酰胺取代的吲哚化合物 |
CN111491929B (zh) | 2017-12-20 | 2023-11-28 | 百时美施贵宝公司 | 可用作tlr抑制剂的氨基吲哚化合物 |
WO2019126083A1 (fr) | 2017-12-20 | 2019-06-27 | Bristol-Myers Squibb Company | Composés de diazaindole |
CA3085942A1 (fr) | 2017-12-20 | 2019-06-27 | Bristol-Myers Squibb Company | Composes d'indole a substitution aryle et heteroaryle |
CN113811299A (zh) * | 2019-03-15 | 2021-12-17 | 博笛生物科技有限公司 | 用于治疗癌症的免疫调控性组合物和方法 |
WO2021150613A1 (fr) | 2020-01-20 | 2021-07-29 | Incyte Corporation | Composés spiro en tant qu'inhibiteurs de kras |
WO2021231526A1 (fr) | 2020-05-13 | 2021-11-18 | Incyte Corporation | Composés de pyrimidine fusionnés utilisés comme inhibiteurs de kras |
WO2022072783A1 (fr) | 2020-10-02 | 2022-04-07 | Incyte Corporation | Composés diones bicycliques en tant qu'inhibiteurs de kras |
BR112023021107A2 (pt) | 2021-04-16 | 2023-12-12 | Gilead Sciences Inc | Compostos de tienopirrol |
US11939328B2 (en) | 2021-10-14 | 2024-03-26 | Incyte Corporation | Quinoline compounds as inhibitors of KRAS |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
CA1271477A (fr) | 1983-11-18 | 1990-07-10 | John F. Gerster | 1h-imidazo[4,5-c]quinoleine-4-amines |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
US5491084A (en) | 1993-09-10 | 1996-02-13 | The Trustees Of Columbia University In The City Of New York | Uses of green-fluorescent protein |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
ATE509102T1 (de) | 1994-07-15 | 2011-05-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
AR006928A1 (es) | 1996-05-01 | 1999-09-29 | Pioneer Hi Bred Int | Una molecula de adn aislada que codifica una proteina fluorescente verde como marcador rastreable para la transformacion de plantas, un metodo para laproduccion de plantas transgenicas, un vector de expresion, una planta transgenica y celulas de dichas plantas. |
AU738513B2 (en) | 1997-02-28 | 2001-09-20 | University Of Iowa Research Foundation, The | Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders |
AU753688B2 (en) | 1997-03-10 | 2002-10-24 | Ottawa Civic Loeb Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
WO1998050547A2 (fr) | 1997-05-07 | 1998-11-12 | Schering Corporation | Recepteur proteique humain du type toll, reactifs connexes et techniques afferentes |
ATE370740T1 (de) | 1997-05-20 | 2007-09-15 | Ottawa Health Research Inst | Verfahren zur herstellung von nukleinsäurekonstrukten |
ES2284247T3 (es) | 1998-04-03 | 2007-11-01 | University Of Iowa Research Foundation | Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos. |
AU3884199A (en) | 1998-05-06 | 1999-11-23 | Ottawa Health Research Institute | Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides |
JP2000119271A (ja) * | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | 1h―イミダゾピリジン誘導体 |
CN1346350A (zh) | 1999-01-22 | 2002-04-24 | 依兰制药公司 | 抑制vla-4介导的白细胞粘着的化合物 |
IL148844A0 (en) | 1999-09-27 | 2002-09-12 | Coley Pharm Group Inc | Methods related to immunostimulatory nucleic acid-induced interferon |
CN1721443A (zh) | 2000-05-25 | 2006-01-18 | 先灵公司 | 人受体蛋白;相关的试剂和方法 |
BR0211962A (pt) | 2001-08-17 | 2005-04-19 | Coley Pharm Group Inc | Combinação de partes de oligonucleotìdeos imuno-estimulantes com atividade melhorada |
US20050004144A1 (en) | 2003-04-14 | 2005-01-06 | Regents Of The University Of California | Combined use of IMPDH inhibitors with toll-like receptor agonists |
BRPI0411514A (pt) * | 2003-06-20 | 2006-08-01 | Coley Pharm Gmbh | antagonistas de receptor toll-like de molécula pequena |
EP1851218A2 (fr) * | 2005-02-23 | 2007-11-07 | 3M Innovative Properties Company | Composes d'imidazoquinolines a substitution hydroxyalkyle et procedes |
JP5247458B2 (ja) * | 2005-11-04 | 2013-07-24 | スリーエム・イノベイティブ・プロパティーズ・カンパニー | ヒドロキシ及びアルコキシ置換1h−イミダゾキノリン及び方法 |
US20100010217A1 (en) * | 2006-03-23 | 2010-01-14 | Valiante Nicholas M | Methods for the preparation of imidazole-containing compounds |
US8027888B2 (en) * | 2006-08-31 | 2011-09-27 | Experian Interactive Innovation Center, Llc | Online credit card prescreen systems and methods |
US20080149123A1 (en) * | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
US7943771B2 (en) * | 2007-01-24 | 2011-05-17 | Chemagis Ltd. | Imiquimod production process |
EP3176169A1 (fr) * | 2007-01-31 | 2017-06-07 | Chongxi Yu | Promédicaments hydrosolubles à charge positive de 1h-imidazo[4,5-c]quinolin-4-amines et composés associés à taux éléves de pénétration cutanée |
EP1972629A1 (fr) * | 2007-03-23 | 2008-09-24 | Mutabilis SA | Nouveaux dérivés d'imidazolo-hétéroaryle ayant des propriétés antibacteriaux |
KR20110095857A (ko) | 2008-09-10 | 2011-08-25 | 칼립시스, 인코포레이티드 | 질환의 치료를 위한 히스타민 수용체의 헤테로시클릭 억제제 |
WO2011068233A1 (fr) * | 2009-12-03 | 2011-06-09 | Dainippon Sumitomo Pharma Co., Ltd. | Imidazoquinolines agissant par l'intermédiaire des récepteurs de type toll (tlr) |
US8728486B2 (en) * | 2011-05-18 | 2014-05-20 | University Of Kansas | Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds |
-
2012
- 2012-10-03 AU AU2012318694A patent/AU2012318694B2/en active Active
- 2012-10-03 US US14/349,254 patent/US9873694B2/en active Active
- 2012-10-03 JP JP2014534658A patent/JP2014528449A/ja active Pending
- 2012-10-03 IN IN948KON2014 patent/IN2014KN00948A/en unknown
- 2012-10-03 WO PCT/US2012/058566 patent/WO2013052550A2/fr active Application Filing
- 2012-10-03 CA CA2850932A patent/CA2850932A1/fr not_active Abandoned
- 2012-10-03 EP EP12837804.9A patent/EP2763677B1/fr active Active
-
2014
- 2014-04-06 IL IL231957A patent/IL231957A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
US9873694B2 (en) | 2018-01-23 |
WO2013052550A3 (fr) | 2014-05-15 |
EP2763677A4 (fr) | 2015-05-20 |
EP2763677A2 (fr) | 2014-08-13 |
CA2850932A1 (fr) | 2013-04-11 |
AU2012318694A1 (en) | 2014-05-22 |
JP2014528449A (ja) | 2014-10-27 |
AU2012318694B2 (en) | 2016-12-22 |
WO2013052550A2 (fr) | 2013-04-11 |
EP2763677B1 (fr) | 2020-02-26 |
IL231957A0 (en) | 2014-05-28 |
US20140242121A1 (en) | 2014-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014KN00948A (fr) | ||
PH12020550552A1 (en) | Inhibitors of hepatitis c virus | |
MY165087A (en) | Neprilysin inhibitors | |
MX342212B (es) | Inhibidores de neprilisina. | |
MY170935A (en) | Neprilysin inhibitors | |
EA026667B9 (ru) | Фармацевтическая композиция для лечения вируса гепатита с | |
MX2013011589A (es) | Metodos y composiciones para tratar enfermedad de parkinson. | |
WO2010108074A3 (fr) | Inhibiteurs de pi3 kinase | |
MX2013006802A (es) | Inhibidores de neprilisina. | |
MX2013007336A (es) | Compuestos de bi-heteroarilo como inhibidores de vps34. | |
MX2013011591A (es) | Métodos y composiciones para tratar enfermedades neurodegenerativas. | |
PH12014501967B1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
MX350746B (es) | Derivados de ciclosporina novedosos para el tratamiento y la prevención de una infección viral. | |
TN2015000574A1 (en) | Compounds and compositions as inhibitors of mek | |
CA2881554C (fr) | Methodes d'inhibition de la fascine | |
MX348393B (es) | Polimorfo de rifaximina y proceso para la preparacion del mismo. | |
PH12015500111A1 (en) | Difluorolactam compositions for ep4-mediated osteo related diseases and conditions | |
ZA201500362B (en) | Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient | |
PH12017500089B1 (en) | Aldosterone synthase inhibitors | |
MX342153B (es) | Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio. | |
WO2013028615A8 (fr) | Nouveaux dérivés de la cyclosporine destinés à traiter et à prévenir des infections virales | |
WO2012164055A3 (fr) | Nouveaux composés, leur synthèse et leur utilisation dans le traitement de la douleur | |
AU2012312301A8 (en) | Compounds useful as inhibitors of choline kinase | |
WO2013015657A3 (fr) | Nouveau composé ayant une activité inhibitrice de l'angiogenèse, procédé de préparation de ce composé et composition pharmaceutique comprenant ce composé | |
WO2012008765A3 (fr) | Composition pharmaceutique pour le traitement ou la prévention du cancer |